These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 16451297)

  • 21. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E; Bonadei I; D'Aloia A; Del Magro F; Piovanelli B; Bontempi L; Curnis A; Dei Cas L
    Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
    Tardif JC; Ford I; Tendera M; Bourassa MG; Fox K;
    Eur Heart J; 2005 Dec; 26(23):2529-36. PubMed ID: 16214830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
    Borer JS; Fox K; Jaillon P; Lerebours G;
    Circulation; 2003 Feb; 107(6):817-23. PubMed ID: 12591750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N; Bhargava B
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
    Müller-Werdan U; Stöckl G; Ebelt H; Nuding S; Höpfner F; Werdan K;
    Exp Gerontol; 2014 Nov; 59():34-41. PubMed ID: 25193811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
    López-Bescós L; Filipova S; Martos R
    Cardiology; 2007; 108(4):387-96. PubMed ID: 17890862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivabradine for chronic heart failure?
    Drug Ther Bull; 2012 Oct; 50(10):117-20. PubMed ID: 23065752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.
    Tardif JC
    Drugs Today (Barc); 2008 Mar; 44(3):171-81. PubMed ID: 18536779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Possibilities of reducing heart rate by I(f)-channel inhibitors].
    Hennersdorf MG
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():150-2. PubMed ID: 16802542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart rate reduction via selective 'funny' channel blockers.
    Bucchi A; Barbuti A; Baruscotti M; DiFrancesco D
    Curr Opin Pharmacol; 2007 Apr; 7(2):208-13. PubMed ID: 17267284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Ivabradine in the Management of Angina Pectoris.
    Giavarini A; de Silva R
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):407-417. PubMed ID: 27475447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Stable angina pectoris. Effective symptom control and cardioprotection with ivabradine].
    MMW Fortschr Med; 2010 May; 152(21):102-3. PubMed ID: 20608138
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
    Tardif JC; Ponikowski P; Kahan T;
    Int J Cardiol; 2013 Sep; 168(2):789-94. PubMed ID: 23138014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel If current inhibitor ivabradine: safety considerations.
    Savelieva I; Camm AJ
    Adv Cardiol; 2006; 43():79-96. PubMed ID: 16936474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug insight: If inhibitors as specific heart-rate-reducing agents.
    Borer JS
    Nat Clin Pract Cardiovasc Med; 2004 Dec; 1(2):103-9. PubMed ID: 16265314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.